Novonesis stock gets a higher target at 420 DKK

Published on 10/08/2026 at 10:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The target rose from DKK 414 to DKK 420 on October 2, 2026, while the rating stayed Neutral. H1 organic sales grew 8.0 percent and adjusted EBITDA margin reached 37.7 percent.

Makroaufnahme von Enzymkristallen und Mikroorganismenkulturen im Detail — Makroaufnahme von Enzymkristallen und Mikroorganismen-Kulturen veranschaulicht die Forschung von Novonesis (Novozymes), ISIN DK0060336014, im Detail, Illustration mit AI erstellt.

Novonesis stock (ISIN DK0060336014) was trading at DKK 436.40 on Nasdaq Copenhagen on October 8, 2026 at 9:59 a.m. CEST, up 1.23 percent from the DKK 431.10 prior close. The latest analyst action lifted the target from DKK 414 to DKK 420 while keeping the rating at Neutral.

Target rises to DKK 420

According to IT Boltwise on October 2, 2026, BNP Paribas raised its Novonesis target to DKK 420 from DKK 414 and retained Neutral. The change came as the company combined stronger sales expectations with a high profitability profile.

The target remains below the current DKK 436.40 price, so the analyst action is better read as a measured reassessment than as a broad bullish signal. Novonesis stock is also 6.15 percent below its 52-week high of DKK 465.00, leaving the quotation below its yearly peak.

Growth and margin set the test

For the first half of 2026, organic sales growth reached 8.0 percent and adjusted EBITDA margin was 37.7 percent, according to IT Boltwise. The company now expects organic sales growth of 7.0 to 8.0 percent for fiscal year 2026, compared with the earlier 5.0 to 7.0 percent range.

Novonesis says its first-half results were released on August 19, 2026. The comparison matters because the new growth range reaches one percentage point above the earlier upper boundary, while the adjusted EBITDA margin outlook remains 37.0 to 38.0 percent.

Acquisition adds a second catalyst

Novonesis completed its acquisition of Australian biotechnology company MicroBioGen on October 1, 2026, after receiving regulatory approvals, Securities.io reported. The deal adds yeast-strain capabilities to a business built around enzymes and microorganisms for industrial applications.

The next quantified checkpoint is the third-quarter report. MarketScreener lists November 4, 2026 as the Q3 2026 earnings release date.

Stock remains below yearly high

Novonesis stock was last at DKK 436.40 on Nasdaq Copenhagen on October 8, 2026 at 9:59 a.m. CEST. Its 52-week range was DKK 336.80 to DKK 465.00, with a market capitalization of DKK 121.3 billion as of October 8, 2026.